{
      "Rank": 1,
      "Acronym": [],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [],
      "ArmGroupDescription": [
            "MPC dose 1 or Placebo",
            "MPC dose 2 or Placebo",
            "MPC dose 3 or Placebo"
      ],
      "ArmGroupInterventionName": [
            "Drug: Mesenchymal Precursor Cells (MPCs)",
            "Drug: Mesenchymal Precursor Cells (MPCs)",
            "Drug: Mesenchymal Precursor Cells (MPCs)"
      ],
      "ArmGroupLabel": [
            "Cohort 1",
            "Cohort 2",
            "Cohort 3"
      ],
      "ArmGroupType": [
            "Experimental",
            "Experimental",
            "Experimental"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT01576328"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [],
      "BaselineDenomCountGroupId": [],
      "BaselineDenomCountValue": [],
      "BaselineDenomUnits": [],
      "BaselineGroupDescription": [],
      "BaselineGroupId": [],
      "BaselineGroupTitle": [],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [],
      "BaselineMeasureParamType": [],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [],
      "BaselineMeasureUnitOfMeasure": [],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "This study is being conducted to assess the overall safety and tolerability of a single intravenous infusion of three doses of Mesenchymal Precursor Cells versus Placebo in subjects with Type 2 Diabetes inadequately controlled on Metformin."
      ],
      "BriefTitle": [
            "Safety Study of Mesenchymal Precursor Cells in Type 2 Diabetes"
      ],
      "CentralContactEMail": [],
      "CentralContactName": [],
      "CentralContactPhone": [],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [],
      "CollaboratorClass": [],
      "CollaboratorName": [],
      "CompletionDate": [
            "October 2015"
      ],
      "CompletionDateType": [
            "Actual"
      ],
      "Condition": [
            "Type 2 Diabetes"
      ],
      "ConditionAncestorId": [
            "D000044882",
            "D000008659",
            "D000004700"
      ],
      "ConditionAncestorTerm": [
            "Glucose Metabolism Disorders",
            "Metabolic Diseases",
            "Endocrine System Diseases"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC18",
            "BC19",
            "All"
      ],
      "ConditionBrowseBranchName": [
            "Nutritional and Metabolic Diseases",
            "Gland and Hormone Related Diseases",
            "All Conditions"
      ],
      "ConditionBrowseLeafAsFound": [
            "Diabetes",
            "Type 2 Diabetes"
      ],
      "ConditionBrowseLeafId": [
            "M6267",
            "M6271",
            "M10791",
            "M24556",
            "M7014"
      ],
      "ConditionBrowseLeafName": [
            "Diabetes Mellitus",
            "Diabetes Mellitus, Type 2",
            "Metabolic Diseases",
            "Glucose Metabolism Disorders",
            "Endocrine System Diseases"
      ],
      "ConditionBrowseLeafRelevance": [
            "high",
            "high",
            "low",
            "low",
            "low"
      ],
      "ConditionMeshId": [
            "D000003920",
            "D000003924"
      ],
      "ConditionMeshTerm": [
            "Diabetes Mellitus",
            "Diabetes Mellitus, Type 2"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "Randomized"
      ],
      "DesignInterventionModel": [
            "Parallel Assignment"
      ],
      "DesignInterventionModelDescription": [],
      "DesignMasking": [
            "Single"
      ],
      "DesignMaskingDescription": [],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [
            "Participant"
      ],
      "DetailedDescription": [],
      "DispFirstPostDate": [],
      "DispFirstPostDateType": [],
      "DispFirstSubmitDate": [],
      "DispFirstSubmitQCDate": [],
      "EligibilityCriteria": [
            "Key Inclusion Criteria:\n\nMale and female subjects who are \u2265 18 and \u2264 80 years old\nSubjects diagnosed with type 2 diabetes at least one year prior to Screening and receiving a stable, therapeutic dose of metformin > 1500 mg/day according to local prescribing information for at least 3 months prior to Screening or the highest tolerated dose > 1000 mg/day documented in the subject's history\nHbA1c > 7.0% and < 10.5% at Screening\nC-peptide > 0.8 ng/mL at Screening\nBody mass index (BMI) > 22 and < 45 kg/m2 at Screening\nBody weight < 150 kg at Screening\n\nKey Exclusion Criteria:\n\nPrior participation in any stem cell study\nWomen who are pregnant, intending to become pregnant during the study period or currently lactating\nHistory of active substance abuse (including alcohol) within the past 2 years. Current alcohol abuse is defined as daily consumption of >3 alcoholic beverage. Current cigarette smoking > 10 cigarettes per day\nSevere hypoglycemia (defined as requiring third party assistance) or repeated and/or frequent hypoglycemia episodes (> 2 episodes/week) within one month prior to Screening\nPatients receiving treatment for type 2 diabetes with diet and exercise alone, insulin therapy within 6 months of Screening except if used transiently for < 7 days for intercurrent illness or any other anti-diabetic medication except metformin within 3 months of Screening\nAny concurrent medical condition/disorder or clinically symptomatic cardiovascular, gastrointestinal (including pancreatitis), renal, hematological, pulmonary, acute or chronic infectious disease, active retinal disease, or other disorder which in the Investigator's opinion would interfere with the subject's ability to complete the trial, would require administration of treatment that could affect the interpretation of the safety and efficacy variables or would preclude safe involvement in the study."
      ],
      "EnrollmentCount": [
            "61"
      ],
      "EnrollmentType": [
            "Actual"
      ],
      "EventGroupDeathsNumAffected": [],
      "EventGroupDeathsNumAtRisk": [],
      "EventGroupDescription": [],
      "EventGroupId": [],
      "EventGroupOtherNumAffected": [],
      "EventGroupOtherNumAtRisk": [],
      "EventGroupSeriousNumAffected": [],
      "EventGroupSeriousNumAtRisk": [],
      "EventGroupTitle": [],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [],
      "EventsTimeFrame": [],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [],
      "FlowAchievementNumSubjects": [],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [],
      "FlowGroupId": [],
      "FlowGroupTitle": [],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [],
      "FlowPeriodTitle": [],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [],
      "InterventionAncestorTerm": [],
      "InterventionArmGroupLabel": [
            "Cohort 1",
            "Cohort 2",
            "Cohort 3"
      ],
      "InterventionBrowseBranchAbbrev": [
            "Hypo",
            "All"
      ],
      "InterventionBrowseBranchName": [
            "Hypoglycemic Agents",
            "All Drugs and Chemicals"
      ],
      "InterventionBrowseLeafAsFound": [],
      "InterventionBrowseLeafId": [
            "M10819"
      ],
      "InterventionBrowseLeafName": [
            "Metformin"
      ],
      "InterventionBrowseLeafRelevance": [
            "low"
      ],
      "InterventionDescription": [
            "Single intravenous infusion of MPCs Dose 1",
            "Single intravenous infusion of MPCs Dose 2",
            "Single intravenous infusion of MPCs Dose 3"
      ],
      "InterventionMeshId": [],
      "InterventionMeshTerm": [],
      "InterventionName": [
            "Mesenchymal Precursor Cells (MPCs)",
            "Mesenchymal Precursor Cells (MPCs)",
            "Mesenchymal Precursor Cells (MPCs)"
      ],
      "InterventionOtherName": [],
      "InterventionType": [
            "Drug",
            "Drug",
            "Drug"
      ],
      "IsFDARegulatedDevice": [],
      "IsFDARegulatedDrug": [],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [],
      "LargeDocDate": [],
      "LargeDocFilename": [],
      "LargeDocHasICF": [],
      "LargeDocHasProtocol": [],
      "LargeDocHasSAP": [],
      "LargeDocLabel": [],
      "LargeDocTypeAbbrev": [],
      "LargeDocUploadDate": [],
      "LastKnownStatus": [],
      "LastUpdatePostDate": [
            "June 2, 2020"
      ],
      "LastUpdatePostDateType": [
            "Actual"
      ],
      "LastUpdateSubmitDate": [
            "June 1, 2020"
      ],
      "LeadSponsorClass": [
            "INDUSTRY"
      ],
      "LeadSponsorName": [
            "Mesoblast, Ltd."
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [
            "Garden Grove",
            "Miami",
            "Orlando",
            "Baton Rouge",
            "New Orleans",
            "Butte",
            "Henderson",
            "Las Vegas",
            "Newington",
            "Cincinnati",
            "Dayton",
            "Dallas",
            "Houston",
            "San Antonio",
            "Salt Lake City",
            "Norfolk",
            "Richmond",
            "Olympia"
      ],
      "LocationContactEMail": [],
      "LocationContactName": [],
      "LocationContactPhone": [],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [],
      "LocationCountry": [
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States"
      ],
      "LocationFacility": [
            "SC Clinical Research",
            "Diabetes Research Institute",
            "Compass Research",
            "Pennington Biomedical Research Center",
            "Tulane University Medical Center",
            "Big Sky Clinical Research",
            "Desert Endocrinology Clinical Research Center-Henderson",
            "Alliance Against Diabetes/AAD Clinical Research",
            "Active Practices and Research",
            "The Carl and Edyth Lindner Center for Research and Education at The Christ Hospital",
            "Providence Health Partners - Center for Clinical Reseach",
            "Dallas Diabetes and Endocrine Center",
            "West Houston Clinical Research Services",
            "Paragon Research Center",
            "Wasatch Clinical Research",
            "National Clinical Research - Norfolk, Inc",
            "National Clinical Research - Richmond, Inc.",
            "Capital Clinical Research Center"
      ],
      "LocationState": [
            "California",
            "Florida",
            "Florida",
            "Louisiana",
            "Louisiana",
            "Montana",
            "Nevada",
            "Nevada",
            "New Hampshire",
            "Ohio",
            "Ohio",
            "Texas",
            "Texas",
            "Texas",
            "Utah",
            "Virginia",
            "Virginia",
            "Washington"
      ],
      "LocationStatus": [],
      "LocationZip": [
            "92844",
            "33136",
            "32806",
            "70808",
            "70112",
            "59701",
            "89052",
            "89101",
            "03801",
            "45219",
            "45439",
            "75230",
            "77055",
            "78205",
            "84107",
            "23502",
            "23294",
            "98502"
      ],
      "MaximumAge": [
            "80 Years"
      ],
      "MinimumAge": [
            "18 Years"
      ],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "A Randomized, Placebo-Controlled Dose-Escalation Study to Assess the Safety and Tolerability of a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Type 2 Diabetes Sub-optimally Controlled on Metformin"
      ],
      "OrgClass": [
            "INDUSTRY"
      ],
      "OrgFullName": [
            "Mesoblast, Ltd."
      ],
      "OrgStudyId": [
            "MSB-DM003"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [],
      "OtherEventSourceVocabulary": [],
      "OtherEventStatsGroupId": [],
      "OtherEventStatsNumAffected": [],
      "OtherEventStatsNumAtRisk": [],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [],
      "OtherOutcomeDescription": [],
      "OtherOutcomeMeasure": [],
      "OtherOutcomeTimeFrame": [],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [],
      "OutcomeDenomCountGroupId": [],
      "OutcomeDenomCountValue": [],
      "OutcomeDenomUnits": [],
      "OutcomeGroupDescription": [],
      "OutcomeGroupId": [],
      "OutcomeGroupTitle": [],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [],
      "OutcomeMeasureDispersionType": [],
      "OutcomeMeasureParamType": [],
      "OutcomeMeasurePopulationDescription": [],
      "OutcomeMeasureReportingStatus": [],
      "OutcomeMeasureTimeFrame": [],
      "OutcomeMeasureTitle": [],
      "OutcomeMeasureType": [],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [],
      "OverallOfficialAffiliation": [
            "Mesoblast, Ltd."
      ],
      "OverallOfficialName": [
            "K Segal, PhD"
      ],
      "OverallOfficialRole": [
            "Study Director"
      ],
      "OverallStatus": [
            "Completed"
      ],
      "OversightHasDMC": [
            "Yes"
      ],
      "PatientRegistry": [],
      "Phase": [
            "Phase 1",
            "Phase 2"
      ],
      "PointOfContactEMail": [],
      "PointOfContactOrganization": [],
      "PointOfContactPhone": [],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [],
      "PrimaryCompletionDate": [
            "October 2013"
      ],
      "PrimaryCompletionDateType": [
            "Actual"
      ],
      "PrimaryOutcomeDescription": [
            "Outcomes include the measurement of the following safety parameters:\n\nAdverse events and serious adverse events(including hypoglycemia)\nVital signs (BP, HR, RR, O2 saturation)\nPhysical examinations\nResults of clinical laboratory tests (hematology, biochemistry, and urinalysis, flow cytometry Class I and Class II PRA % with specificity, antibovine and antimurine antibody analysis)\nPulmonary function test\nElectrocardiograms\nChest X-ray\nFundus oculi examination"
      ],
      "PrimaryOutcomeMeasure": [
            "Primary objective of the study is to assess the safety and tolerability of MPC therapy"
      ],
      "PrimaryOutcomeTimeFrame": [
            "116 Weeks"
      ],
      "ReferenceCitation": [
            "Skyler JS, Fonseca VA, Segal KR, Rosenstock J; MSB-DM003 Investigators. Allogeneic Mesenchymal Precursor Cells in Type 2 Diabetes: A Randomized, Placebo-Controlled, Dose-Escalation Safety and Tolerability Pilot Study. Diabetes Care. 2015 Sep;38(9):1742-9. doi: 10.2337/dc14-2830. Epub 2015 Jul 7."
      ],
      "ReferencePMID": [
            "26153271"
      ],
      "ReferenceType": [
            "derived"
      ],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [],
      "ResponsiblePartyInvestigatorFullName": [],
      "ResponsiblePartyInvestigatorTitle": [],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Sponsor"
      ],
      "ResultsFirstPostDate": [],
      "ResultsFirstPostDateType": [],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [],
      "ResultsFirstSubmitQCDate": [],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [],
      "SecondaryIdDomain": [],
      "SecondaryIdLink": [],
      "SecondaryIdType": [],
      "SecondaryOutcomeDescription": [],
      "SecondaryOutcomeMeasure": [],
      "SecondaryOutcomeTimeFrame": [],
      "SeeAlsoLinkLabel": [],
      "SeeAlsoLinkURL": [],
      "SeriousEventAssessmentType": [],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [],
      "SeriousEventSourceVocabulary": [],
      "SeriousEventStatsGroupId": [],
      "SeriousEventStatsNumAffected": [],
      "SeriousEventStatsNumAtRisk": [],
      "SeriousEventStatsNumEvents": [],
      "SeriousEventTerm": [],
      "StartDate": [
            "April 2012"
      ],
      "StartDateType": [],
      "StatusVerifiedDate": [
            "June 2020"
      ],
      "StdAge": [
            "Adult",
            "Older Adult"
      ],
      "StudyFirstPostDate": [
            "April 12, 2012"
      ],
      "StudyFirstPostDateType": [
            "Estimate"
      ],
      "StudyFirstSubmitDate": [
            "April 9, 2012"
      ],
      "StudyFirstSubmitQCDate": [
            "April 10, 2012"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 07, 2022"
      ],
      "WhyStopped": []
}